A5085459947- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Childhood Cancer Survivors' Quality of Life
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Family Support in Illness
- Palliative Care and End-of-Life Issues
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- Frailty in Older Adults
- Nutrition and Health in Aging
- Glioma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- BRCA gene mutations in cancer
- Sleep and related disorders
- Optimism, Hope, and Well-being
- Circadian rhythm and melatonin
- Prostate Cancer Treatment and Research
- Chemotherapy-related skin toxicity
Moffitt Cancer Center
2016-2025
Roche (Sweden)
2020
Janssen (Belgium)
2020
Janssen (Switzerland)
2020
Janssen Scientific Affairs (United States)
2020
University of South Florida
2017-2019
Jimma University
2019
University of Kentucky
2015-2019
Georgia Southern University
2019
James Cook University
2017
The success of chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed/refractory hematologic malignancies is leading to a growing number survivors treated this regimen. To our knowledge, no previous studies have examined neurocognitive performance adult CAR recipients, despite high rates neurotoxicity and cytokine release syndrome (CRS) the acute treatment period. This study changes first year after for non-Hodgkin lymphoma (NHL). Putative risk factors worsening...
Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses in patients with relapsed/refractory hematologic malignancies. Immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release (CRS) are common may place at risk for longer-term cognitive impairment. This study examined changes cognition the first year after CD19-directed CAR lymphoma, as well therapy-specific risk-factors (e.g., ICANS, CRS) nonspecific factors baseline quality of life, frailty)...
118 Background: The Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) is used in trials and clinical practice to monitor patient-reported RNT-relevant symptoms toxicities advanced metastatic castrate-resistant prostate cancer (mCRPC) patients receiving RNT. This study examined FACT-RNT feasibility preliminary validity for U.S. Methods: Patients scheduled start 177Lu-PSMA-617 mCRPC at Moffitt Center from October 2023 – March 2024 completed outcome (PRO) measures before...
Background Fatigue is a common and disabling side effect of targeted therapies such as tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia (CML). The goal the current study was conduct pilot randomized trial first cognitive behavioral intervention developed for fatigue due therapy. Methods Patients with CML treated TKI who were reporting moderate severe recruited 2:1 therapy therapy–related (CBT‐TTF) delivered via FaceTime iPad or waitlist control (WLC) group. outcomes...
Abstract Background Racial and ethnic disparities are well‐documented in cancer outcomes such as disease progression survival, but less is known regarding potential symptom burden. Aims The goal of this retrospective study was to examine differences burden by race ethnicity a large sample patients. We hypothesized that racial minority patients would report greater than non‐Hispanic White Methods results A total 5798 completed the Edmonton Symptom Assessment Scale—revised (ESAS‐r‐CSS) at...
Abstract Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity the first 90 days after treatment. Hematologic cancer patients treated axi‐cel ( N = 103, mean age 61, 39% female) completed SF‐36 or PROMIS‐29 QOL questionnaires prior to treatment after. PRO‐Common Terminology Criteria for...
Background: Clinicians must closely monitor patients for toxicities after chimeric antigen receptor T-cell therapy (CAR-T). Patient-reported outcomes (PROs) (e.g., toxicities, quality of life) and activity data steps, sleep) may complement clinicians’ observations. This study tested the feasibility acceptability collecting PROs from with hematologic malignancies during CAR-T explored preliminary patterns. Methods: Participants wore a Fitbit tracker completed at several timepoints through...
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts chemotherapy or surgery. We aimed develop PRO measure PC patients receiving RNT. <b>Methods:</b> First, we identified relevant symptoms/toxicities by reviewing published trials and interviews RNT (<i>n</i> = 29), caregivers 14), clinicians 11). Second, selected items...
Social isolation and social connectedness are health determinants aspects of well-being with strong associations psychological distress. This study evaluated relationships among isolation, connectedness, distress (i.e., depression, anxiety) over 1 year in young adult (YA) cancer survivors 18-39 years old.
Background Increases in fatigue, depressive symptomatology, and cognitive impairment are common after the initiation of androgen deprivation therapy (ADT) for prostate cancer. To date, no studies have examined potential role inflammation development these symptoms ADT recipients. The goal current study was to examine circulating markers as mediators change related receipt ADT. Methods Patients treated with cancer (ADT+; n = 47) were assessed around time 6 12 months later. An age‐...
Improvements in supportive care have enabled allogeneic hematopoietic cell transplantation (HCT) to be performed increasingly older patients. HCT is associated with neurocognitive impairment, which may exacerbated adults due normal decline aging. The goal of this study was evaluate whether increasing age recipients worse outcomes over time relative a matched sample individuals without cancer. Patients (n = 140; 42% female; M age, 51 years; range, 20 76 31% acute myelogenous leukemia)...
To better understand the disproportionate burdens from cancer, cardiovascular disease, diabetes mellitus, stroke, and other chronic conditions related to energy balance, we studied diet physical activity patterns in younger older adults rural Appalachia by using a nonclinical, cross-sectional, community-based sampling approach.A total of 651 (ages 18-59) 254 ≥60) Appalachians were recruited 43 churches or community organizations. Participants answered questions about fruit vegetable intake...